Pink Sheet, June 13, 2024: NCHR quoted from FDA listening session on optimizing the advisory committee process.
Read More »Author: Caroline Bradford
The Patient, Consumer, and Public Health Coalition Testified at an FDA Listening Session on Advisory Committees
June 13, 2024: The Patient, Consumer, and Public Health coalition testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs, the inherent conflicts of interests of committee members, and inadequate training provided to appointees.
Read More »NCHR’s Public Comment on Early Alzheimer’s Disease: Developing Drugs for Treatment; Draft Guidance for Industry
June 10, 2024: NCHR disagrees with assumptions made in FDA guidance aimed at developing drugs for treatment of early stages of Alzheimer’s dementia.
Read More »Readers respond to mothers in treatment for opioid use disorder, pandemic models, and more
STAT, June 8, 2024: Our Letter to the Editor at STAT News disagreed with the first Opinion commentary urging more use of antipsychotics for dementia patients. We explain that these drugs too often kill older patients or serve as chemical straight jackets,
Read More »NCHR Comment on Proposed Information Collection Request; Comment Request; POTW Influent PFAS Study Data Collection
May 28, 2024: NCHR supports the EPA’s proposed plan to collect data on PFAS contaminants in public water sources but urges EPA to protect public health by expanding the plan to test for many more PFAS chemicals and at more testing plants.
Read More »